US Food and Drug Administration Issues Nationwide Recall of Blood Pressure Medication Over Cancer Concerns
In a move to address potential health risks, the US FDA has initiated a nationwide recall of over 580,000 bottles of blood pressure medication prazosin hydrochloride due to contamination with a cancer-causing chemical. Teva Pharmaceuticals USA and Amerisource Health Services have issued voluntary recalls of various strength prazosine capsules, following an investigation by the regulatory agency.
The FDA has classified the affected lots as having a Class II risk classification, indicating that some of the recalled medication may contain nitrosamine impurities. N-nitrosamines are a class of potentially cancer-causing chemicals that can form during manufacturing or storage of pharmaceuticals.
Prazosin hydrochloride is commonly prescribed to relax blood vessels and lower blood pressure, as well as treat nightmares and other sleep disturbances associated with post-traumatic stress disorder (PTSD). With millions of patients relying on the medication for their health needs, the FDA's swift action aims to mitigate potential health risks.
As part of its efforts, the FDA has given the affected lots a priority for review and is urging consumers not to use the recalled products. Patients currently taking prazosin hydrochloride are advised to contact their healthcare provider or pharmacist about alternative treatments and guidance on safely transitioning to an approved medication.
This latest development underscores the ongoing importance of regulatory oversight in safeguarding public health, particularly when it comes to life-saving medications like prazosin hydrochloride.
				
			In a move to address potential health risks, the US FDA has initiated a nationwide recall of over 580,000 bottles of blood pressure medication prazosin hydrochloride due to contamination with a cancer-causing chemical. Teva Pharmaceuticals USA and Amerisource Health Services have issued voluntary recalls of various strength prazosine capsules, following an investigation by the regulatory agency.
The FDA has classified the affected lots as having a Class II risk classification, indicating that some of the recalled medication may contain nitrosamine impurities. N-nitrosamines are a class of potentially cancer-causing chemicals that can form during manufacturing or storage of pharmaceuticals.
Prazosin hydrochloride is commonly prescribed to relax blood vessels and lower blood pressure, as well as treat nightmares and other sleep disturbances associated with post-traumatic stress disorder (PTSD). With millions of patients relying on the medication for their health needs, the FDA's swift action aims to mitigate potential health risks.
As part of its efforts, the FDA has given the affected lots a priority for review and is urging consumers not to use the recalled products. Patients currently taking prazosin hydrochloride are advised to contact their healthcare provider or pharmacist about alternative treatments and guidance on safely transitioning to an approved medication.
This latest development underscores the ongoing importance of regulatory oversight in safeguarding public health, particularly when it comes to life-saving medications like prazosin hydrochloride.